ANKE BIO(SZ:300009)2022-12-06 08:36Group 1: Precision Medicine Strategy - The company has expanded from gene engineering pharmaceuticals to precision medicine since 2014, focusing on precision diagnostics and treatments [4] - Precision diagnostics include gene sequencing and testing, with the establishment of a third-party testing platform and the acquisition of a company specializing in gene testing [4] - The establishment of Anke Clover Company focuses on tumor CT-RNA testing, enhancing the company's precision medicine portfolio [4] Group 2: Precision Treatment Developments - The company is actively developing targeted therapies for tumors, including small molecule and large molecule antibody drugs, with the Her-2 monoclonal antibody nearing completion of Phase I clinical trials [4][5] - A contract was signed to acquire PD-1 humanized antibody technology, which is expected to expedite clinical trials significantly [5] - The company has entered the cell therapy field through a 20% stake in a partner company, with ongoing clinical trials in Anhui [5] Group 3: Resource Integration and Subsidiary Management - The company is strategically investing in subsidiaries like Anke Clover and Boshengji to enhance its precision medicine layout, focusing on complementary strengths [5][6] - The full subsidiary, Zhongde Meilian, has performed well this year, with plans to integrate international resources for further development in prenatal screening and second-generation sequencing [6] Group 4: Product Development and Market Strategy - The company is working on long-acting products, with clinical trials for long-acting growth hormone expected to complete by the end of next year [6] - The growth hormone market is anticipated to expand due to increasing patient populations and reasonable pricing for growth hormone powder injections [7] - The company is also focusing on the development of small molecule drugs for cancer and viral infections, alongside modernizing traditional Chinese medicine [7]